- Ofatumumab
sclerosis . Ofatumumab has also received conditional approval in Europe for the treatment of refractory chronic lymphocytic leukemia. This makes ofatumumab the first marketing application for an antibody ... that will be available for patients with refractory CLL. Mechanism Ofatumumab targets an epitope different from rituximab and most other CD20 directed antibodies. Ofatumumab binds to both the small ... News 2009 4384.aspx FDA Approves Ofatumumab Arzerra for Patients With CLL Refractory to Fludarabine ... chronic lymphocytic leukemia in 2010. Clinical trials Status of clinical trials of ofatumumab conducted ... arthritis RA Phase III &ndash OFA110635 GEN410 &ndash Ofatumumab in adult RA patients who have had ... of Ofatumumab in Adult RA Patients Who Had an Inadequate Response to MTX Therapy ref Phase III &ndash OFA110634 GEN411 &ndash Ofatumumab in adult RA patients who have had an inadequate response to TNF alpha antagonist therapy ref ClinicalTrialsGov NCT00603525 Investigating Clinical Efficacy of Ofatumumab ... large B cell lymphoma DLBCL &ndash Phase III ref ClinicalTrialsGov NCTNCT01014208 Ofatumumab Versus ... of ofatumumab, a fully human monoclonal anti CD20 antibody, in patients with relapsed or refractory ... cgi pmidlookup?view long&pmid 18003886 cite journal author Zhang B title Ofatumumab journal ... drug stub es Ofatumumab it Ofatumumab ... more details
|
- HuMax
HuMax is an abbreviation for human monoclonal antibody targeting... , used by the pharmaceutical company Genmab in trade names. Examples include HuMax CD4 zanolimumab HuMax CD20 ofatumumab HuMax Epidermal growth factor receptor EGFr zalutumumab Category Monoclonal antibodies ... more details
|
- Genmab
worth 1.6 billion for the antibody ofatumumab. Besides GSK, Genmab also has licensing deals ... news pressreleases newsitem.asp?id 2005 0224 01 ref The Company s first product, Arzerra ofatumumab ... a deal with GlaxoSmithKline to co develop and commercialize ofatumumab, which is a drug that could ... amended the agreement in July 2010. GSK has taken responsibility for developing ofatumumab in autoimmune indications while continuing to jointly develop ofatumumab with Genmab in oncology indications ... pipeline, as of September 2010. class wikitable Product Disease Indications Phase Partner Ofatumumab 20 Studies Chronic lymphocytic leukemia CLL III GSK Ofatumumab Non Hodgkin s Lymphoma NHL III GSK Ofatumumab Rheumatoid arthritis RA III GSK Ofatumumab Diffuse Large B cell Lymphoma DLBCL III GSK Ofatumumab Relapsing Remitting Multiple Sclerosis RRMS II GSK Ofatumumab Waldenstrom s Macroglobulinemia ... more details
|
- List of drugs: Aq-Ar
Nonproprietary Name INN artilide International Nonproprietary Name INN arz Ofatumumab Arzerra ... more details
|
- Ocrelizumab
CD20 antagonist. Ofatumumab HuMax CD20 a fully human CD20 antagonist. References reflist Monoclonals ... more details
|
- ATC code L01
L01XC06 Cetuximab L01XC07 Bevacizumab L01XC08 Panitumumab L01XC09 Catumaxomab L01XC10 Ofatumumab ... more details
|
- List of drugs: O-Op
Name INN ofatumumab International Nonproprietary Name INN oglufanide disodium United States ... more details
|
- Rituximab
90 95 human B cell depleting agent. ofatumumab HuMax CD20 a fully human B cell depleting agent. ref name titleGenmab.com HuMax CD20 ofatumumab cite web url http www.genmab.com ScienceAndResearch ProductsinDevelopment HuMax CD20.aspx title Genmab.com HuMax CD20 ofatumumab accessdate 2007 12 03 ... more details
|
- CD20
s and leukemias . The anti CD20 mAB Ofatumumab Genmab was approved by FDA in Oct 2009 for Chronic ... more details
|
- Belimumab
approved for some indications. Ocrelizumab , ofatumumab and third generation anti CD20 monoclonals ... more details
|
- Therapies under investigation for multiple sclerosis
name ReferenceA cite journal author Castillo J, Milani C, Mendez Allwood D title Ofatumumab, a second ... Opin Investig Drugs volume 9 issue 11 pages 1206 15 year 2008 month November pmid 18951300 ref Ofatumumab ... more details
|
- Waldenström's macroglobulinemia
Alethine, Dolastatin 10, Cyclophosphamide , Ibritumomab Yttrium Y 90 Ibritumomab , ABT 263, Ofatumumab ... more details
|
- List of monoclonal antibodies
diseases Ofatumumab ref name WHOList93 Arzerra mab human CD20 chronic lymphocytic leukemia etc. Olaratumab ... more details
|
Encyclopedia
top
